EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder
Portfolio Pulse from Vandana Singh
Adial Pharmaceuticals (NASDAQ:ADIL) has advanced to the second cohort in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. The study, which began in June 2024, is expected to conclude in Q4 2024, with topline results anticipated in the same quarter. The results will inform the design of a Phase 3 Clinical Trial.
July 23, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals has moved to the second cohort in its pharmacokinetics study of AD04 for Alcohol Use Disorder. The study's results, expected in Q4 2024, will be crucial for the design of a Phase 3 Clinical Trial and subsequent FDA engagement.
The progression to the second cohort in the pharmacokinetics study of AD04 is a positive development for Adial Pharmaceuticals. The anticipated results in Q4 2024 will be critical for the design of a Phase 3 Clinical Trial and FDA engagement, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100